Ticker

Analyst Price Targets — PAM

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
May 20, 2024 9:16 pmLilyanna YangHSBC$46.00$48.87TheFly Pampa Energia upgraded to Hold from Reduce at HSBC

Latest News for PAM

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia

Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, January 7, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, has started a Phase 1 clinical study of NTX-253.

GlobeNewsWire • Jan 7, 2026
Pampa Energia: The Turning Point In Argentina's Most Resilient Energy Player

Pampa's Q3 confirmed accelerating shale growth, improving margins, and a stronger portfolio mix, supporting my buy stance as the company transitions from resilience to structural expansion. Management guides for sharp production increases through 2026-2027, alongside declining lifting costs and a heavy capex cycle fully supported by a solid balance sheet. Despite a 30% rally since August, Pampa still trades at a…

Seeking Alpha • Dec 6, 2025

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

Senate Trading Disclosures

NameTransaction DateTypeAssetAmountLink

No House trades found for PAM.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top